Early patient experiences with montelukast orally disintegrating tablets in Japan

Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and/or allergic rhinitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223208

Enrollment

200

Registered

2016-05-19

Start date

2016-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthama Allergic rhinitis

Interventions

investigational material(s) Generic name etc : montelukast od INN of investigational material : Montelukast Sodium Therapeutic category code : 449 Other antiallergic agents Dosage and Administration f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20 years old or older at the time of registration. Patients taking montelukast sodium OD tablets for asthma or AR treatment at enrollment. Patients who have taken montelukast sodium OD tablets for 2 weeks or more at enrollment. Patients who can understand and complete Japanese questionnaires.

Exclusion criteria

Exclusion criteria: Patients for whom montelukast sodium OD tablets are prescribed for the first time at enrollment.

Design outcomes

Primary

Measure	Time frame
other Orally disintegrating tablets (ODTs) offer a valuable treatment option, particularly when swallowing solid tablets with water is difficult or inconvenient. Montelukast is an effective treatment for asthma and allergic rhinitis (AR), and an ODT formulation became available in Japan in 2015. This study investigated levels of satisfaction with this new formulation among adults with asthma and/or AR in Japan.	—

Measure

Time frame

other Orally disintegrating tablets (ODTs) offer a valuable treatment option, particularly when swallowing solid tablets with water is difficult or inconvenient. Montelukast is an effective treatment for asthma and allergic rhinitis (AR), and an ODT formulation became available in Japan in 2015. This study investigated levels of satisfaction with this new formulation among adults with asthma and/or AR in Japan.

—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026